Video

Role of Venetoclax in Treatment of AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

Related Videos
Related Content
3D visualization of natural killer cells | Image Credit: © N0X - stock.adobe.com
May 22nd 2025

Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Published: May 20th 2025 | Updated: May 20th 2025

Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

Alana Hippensteele, Lead Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
CAR T-cell visualization | Image Credit: © Wimon - stock.adobe.com
May 14th 2025

Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor